NCT05755009

High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor

High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor: A Single-arm, Single-center, Phase II Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Jiangxi Provincial Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore the efficacy and safety of high- and low-dose radiotherapy (HD-RT/LD-RT) combined with envafolimab (I) in the treatment of metastatic solid tumors that have failed first-line immunotherapy or above.

Conditions

• Metastatic Cancer

Interventions

Type	Name	Description
RADIATION	High- and Low-dose radiotherapy	High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.

Timeline

• Start date: 2023-03-01
• Primary completion: 2024-02-20
• Completion: 2025-02-20
• First posted: 2023-03-06
• Last updated: 2023-03-07

Locations

2 sites across 1 country: China